Tecentriq (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
|Therapeutic area (MeSH)||
|Human ATC code||